JP2021530249A5 - - Google Patents
Info
- Publication number
- JP2021530249A5 JP2021530249A5 JP2021523582A JP2021523582A JP2021530249A5 JP 2021530249 A5 JP2021530249 A5 JP 2021530249A5 JP 2021523582 A JP2021523582 A JP 2021523582A JP 2021523582 A JP2021523582 A JP 2021523582A JP 2021530249 A5 JP2021530249 A5 JP 2021530249A5
- Authority
- JP
- Japan
- Prior art keywords
- myxoma virus
- myxv
- cells
- use according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697581P | 2018-07-13 | 2018-07-13 | |
| US62/697,581 | 2018-07-13 | ||
| PCT/US2019/041700 WO2020014670A1 (en) | 2018-07-13 | 2019-07-12 | Methods of treating cancer with tnf expressing myxoma virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530249A JP2021530249A (ja) | 2021-11-11 |
| JP2021530249A5 true JP2021530249A5 (cg-RX-API-DMAC7.html) | 2022-07-19 |
Family
ID=69141734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523582A Pending JP2021530249A (ja) | 2018-07-13 | 2019-07-12 | Tnf発現粘液腫ウイルスで癌を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12257278B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3820491A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021530249A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210031485A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112996908A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019300162A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3106202A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL280060A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021000505A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202100305SA (cg-RX-API-DMAC7.html) |
| TW (1) | TW202024326A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020014670A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100305SA (en) | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
| EP3946373A4 (en) * | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | FAST-PP14-EXPRESSING ONCOLYTIC MYXOMAVIRUS FOR TREATMENT OF BLOOD CANCER |
| CN114615988A (zh) * | 2019-09-02 | 2022-06-10 | 亚利桑那州立大学董事会 | 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台 |
| US20240091284A1 (en) * | 2019-10-10 | 2024-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus comprising immunomodulatory transgenes and uses thereof |
| JP2024508920A (ja) * | 2021-03-01 | 2024-02-28 | オンコミクス セラピューティクス,インク. | 多武装の粘液腫ウイルス |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| WO2007143545A2 (en) * | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
| WO2011156273A1 (en) | 2010-06-06 | 2011-12-15 | Mount Sinai School Of Medicine | Recombinant rna viruses and uses thereof |
| EP2717887B1 (en) * | 2011-06-09 | 2017-12-27 | University of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
| ES2895977T3 (es) * | 2013-11-28 | 2022-02-23 | Bavarian Nordic As | Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus |
| AU2016313969B2 (en) | 2015-06-19 | 2021-12-23 | Sillajen, Inc. | Compositions and methods for viral embolization |
| WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| TW201825511A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現免疫檢查點調節子的溶瘤病毒 |
| SG11202100305SA (en) | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
| BR112021002639A2 (pt) | 2018-08-16 | 2021-05-11 | Musc Foundation For Research Development | vírus recombinantes do mixoma e usos dos mesmos |
| CA3112788A1 (en) | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| EP3946373A4 (en) | 2019-03-28 | 2023-01-11 | Arizona Board of Regents, a Body Corporate of the State of Arizona, acting for and on behalf of Arizona State University | FAST-PP14-EXPRESSING ONCOLYTIC MYXOMAVIRUS FOR TREATMENT OF BLOOD CANCER |
| CN114615988A (zh) | 2019-09-02 | 2022-06-10 | 亚利桑那州立大学董事会 | 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台 |
| CA3152787A1 (en) | 2019-09-02 | 2021-03-11 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers |
-
2019
- 2019-07-12 SG SG11202100305SA patent/SG11202100305SA/en unknown
- 2019-07-12 TW TW108124789A patent/TW202024326A/zh unknown
- 2019-07-12 US US17/259,849 patent/US12257278B2/en active Active
- 2019-07-12 EP EP19834625.6A patent/EP3820491A4/en not_active Withdrawn
- 2019-07-12 WO PCT/US2019/041700 patent/WO2020014670A1/en not_active Ceased
- 2019-07-12 KR KR1020217004009A patent/KR20210031485A/ko not_active Ceased
- 2019-07-12 CN CN201980059900.4A patent/CN112996908A/zh active Pending
- 2019-07-12 AU AU2019300162A patent/AU2019300162A1/en not_active Abandoned
- 2019-07-12 MX MX2021000505A patent/MX2021000505A/es unknown
- 2019-07-12 JP JP2021523582A patent/JP2021530249A/ja active Pending
- 2019-07-12 CA CA3106202A patent/CA3106202A1/en active Pending
-
2021
- 2021-01-10 IL IL280060A patent/IL280060A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives | |
| Bartlett et al. | Oncolytic viruses as therapeutic cancer vaccines | |
| Marchini et al. | Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade | |
| Nguyen et al. | Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer | |
| Liu et al. | Gene therapy progress and prospects cancer: oncolytic viruses | |
| Francescangeli et al. | COVID-19–Induced modifications in the tumor microenvironment: do they affect cancer reawakening and metastatic relapse? | |
| Wu et al. | The role of pyroptosis in modulating the tumor immune microenvironment | |
| Zou et al. | Combining of oncolytic virotherapy and other immunotherapeutic approaches in cancer: a powerful functionalization tactic | |
| Zhu et al. | Recent advances in oncolytic virus therapy for hepatocellular carcinoma | |
| Sanchala et al. | Oncolytic herpes simplex viral therapy: a stride toward selective targeting of cancer cells | |
| Forbes et al. | Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses | |
| CN110325200B (zh) | 治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| de la Nava et al. | Immunovirotherapy for pediatric solid tumors: A promising treatment that is becoming a reality | |
| Alvarez-Breckenridge et al. | Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection | |
| Moehler et al. | Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1 | |
| Gao et al. | Targeting p53 for neuroinflammation: New therapeutic strategies in ischemic stroke | |
| Hu et al. | The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them | |
| Huang et al. | Innate immunity and immunotherapy for hemorrhagic shock | |
| Svyatchenko et al. | Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines | |
| Sheik | Targeting key transcription factors in hepatocellular carcinoma | |
| De Silva et al. | Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses | |
| Shao et al. | Oncolytic virotherapy in peritoneal metastasis gastric cancer: the challenges and achievements | |
| Chou et al. | In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles | |
| Franks et al. | The role of natural killer cells in oncolytic virotherapy: friends or foes? | |
| Haidar | Oncolytic viruses: from basics to challenges to innovation |